VioQuest Pharmaceuticals Doses First Patient In Phase I/IIa Clinical Trial With VQD-001 (Sodium Stibogluconate) For Treatment Of Solid Tumors
Wed, 27 Sep 2006 07:00 AM EST
... VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VQPH), announced today that it has dosed the first patient in its Phase I/IIa clinical trial of VQD-001, Sodium Stibogluconate (SSG), for evaluation of solid tumors, at the MD Anderson Cancer Center. [click link for full article] ...
Related Topics
- Clinical Trials
- Patient Issues
- Sodium
- Sodium Bicarbonate
- Personal Medical Records
- Pharmacology
- Sodium Flouride
- Pancreatic Cancer
- Trastuzumab
- Psychopharmacology
- Crohn's Disease
- Tarceva
- Sodium Azide
- Advocacy
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Depression
- Western/Clinical Treatment and Therapy
- Sodium cyanide
- Bevacizumab Injection

Not Signed In -


